Genomics of Drug Sensitivity in Cancer |
GSK650394
|
Synonyms |
GSK-650394, GSK 650394
|
Targets |
SGK2, SGK3
|
Target pathway |
Other
|
PubCHEM ID |
25022668
|
Jsmol |
|
Download molecule |
25022668
|
PUBCHEM IUPAC INCHI |
InChI=1S/C25H22N2O2/c28-25(29)20-11-10-18(12-21(20)17-8-4-5-9-17)23-15-27-24-22(23)13-19(14-26-24)16-6-2-1-3-7-16/h1-3,6-7,10-15,17H,4-5,8-9H2,(H,26,27)(H,28,29)
|
Smiles |
O=C(O)C4(=C(C=C(C=3(C1(=C(N=CC(=C1)C2(=CC=CC=C2))NC=3)))C=C4)C5(CCCC5))
|
Cluster number |
44
|
calculated LogS |
-7,873
|
Molecular weight |
382,462
|
calculated LogP |
5,5793
|
H-Acceptors |
4
|
H-Donors |
2
|
Ro5 violations |
1
|
Druglikeness |
-2,4554
|
DrugScore |
0,17418176572543
|
Mutagenic |
none
|
Tumorigenic |
none
|
Reproductive Effective |
none
|
Irritant |
none
|
Fish Toxicity |
High FHMT
|
Fish Toxicity2 |
1,5988
|
Rat Acute Toxicity |
3,0849
|
Acute Oral Toxicity |
II
|
Caco-2 Permeability |
Caco2-
|
Caco-2 Permeability2 |
0,8733
|
P-glycoprotein Substrate |
Non-substrate
|
P-glycoprotein Inhibitor |
Non-inhibitor
|
P-glycoprotein Inhibitor2 |
Non-inhibitor
|
Human Ether-a-go-go-Related Gene Inhibition |
Weak inhibitor
|
Human Ether-a-go-go-Related Gene Inhibition2 |
Non-inhibitor
|
Tetrahymena Pyriformis Toxicity |
High TPT
|
Tetrahymena Pyriformis Toxicity2 |
0,5707
|
AMES Toxicity |
Non AMES toxic
|
CYP450 2C9 Substrate |
Non-substrate
|
CYP450 3A4 Substrate |
Non-substrate
|
CYP450 3A4 Inhibitor |
Non-inhibitor
|
CYP450 2C19 Inhibitor |
Non-inhibitor
|
CYP450 2C9 Inhibitor |
Non-inhibitor
|
CYP450 2D6 Inhibitor |
Non-inhibitor
|
CYP450 1A2 Inhibitor |
Inhibitor
|
CYP450 2D6 Substrate |
Non-substrate
|
Biodegradation |
Not ready biodegradable
|
Carcinogenicity (Three-class) |
Non-carcinogens
|
Carcinogens |
Non-required
|
Blood-Brain Barrier |
BBB+
|
CYP Inhibitory Promiscuity |
Low CYP Inhibitory Promiscuity
|
Honey Bee Toxicity |
Low HBT
|
Renal Organic Cation Transporter |
Non-inhibitor
|
Subcellular localization |
Mitochondria
|
Human Intestinal Absorption |
HIA+
|
Aqueous solubility |
-3,4953
|